Over the past two decades, the treatment landscape for type 2 diabetes has expanded beyond traditional agents like sulfonylureas and metformin. Newer drug classes, including GLP‑1 receptor agonists (GLP-1 RAs) and sodium-glucose cotransporter-2 (SGLT2) inhibitors, offer alternative mechanisms of action, improved safety profiles, and more individualized treatment options tailored to patient needs and comorbidities. These advances have enhanced overall glycemic control while minimizing side effects such as hypoglycemia and weight gain, leading to more sustainable long-term management.
Think you know GLP‑1 RAs? Here’s a quick question to put your knowledge to the test! References : Diabetes Care, Diabetes Metabolism Research and Reviews, Cardiovascular Diabetology, and The Lancet Diabetes & Endocrinology ##Disclaimer## The content provided on Docplexus is intended for educational purposes…
